Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DN-2024002
- Development stage
- Preclinical
- Lead developer
- Daehan Nupharm
- Modality
- Small Molecules
01
Overview
DN-2024002 is a small molecule drug candidate being developed by the South Korean pharmaceutical company Daehan Nupharm for the treatment of hyperlipidemia. Currently in the formulation research stage, the project aims to address lipid metabolism disorders. As a pipeline asset, specific details regarding its molecular target (such as HMG-CoA reductase or PCSK9) and its precise mechanism of action have not been publicly disclosed. The development of DN-2024002 is part of Daehan Nupharm's broader strategy to expand its portfolio in the cardiovascular and metabolic disease therapeutic areas through formulation optimization and small molecule innovation.
Beyond the preview
Go deeper on DN-2024002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DN-2024002.